Trusted by pharma teams across Europe
Ariya is built by phamax, a pharma strategy and intelligence company working with pharmaceutical teams across Europe and globally.
COMPETITIVE INTELLIGENCE FOR PHARMA
Ariya is an AI-powered competitive intelligence analyst for pharma. It continuously monitors your competitive field, explains why each signal matters, and recommends what your team should consider doing next.
Request a tailored demoThe analyst who doesn't sleep.
VX-114 label extended to adolescents, beyond adults only
Recommended response
Closes the gap fastest, but competes for medical capacity this quarter.
Trusted by pharma teams across Europe
Ariya is built by phamax, a pharma strategy and intelligence company working with pharmaceutical teams across Europe and globally.
Traditional CI
Ariya
Ariya recommends. Your team decides.
01
Ariya continuously watches the public sources and competitors that matter to your strategy.
02
It connects each signal to your market, product, evidence and strategic context.
03
It proposes response options, supported by evidence, confidence and explicit reasoning.
04
Your team captures what was decided, by whom and why, creating a usable decision history.
The same illustrative signal, followed through the workspace.
01
See the change, the original evidence and the relevant context together.
VX-114 label extended to adolescents (12–17)
02
Ariya explains the strategic meaning instead of forwarding another link.
Confidence
03
Move from signal to an evidence-backed response, then keep a record of what the team decided.
Response options
Closes the gap fastest. Competes for medical capacity this quarter.
Fast and low cost. Defensive only; does not change the evidence position.
Preserves budget. Risks conceding the segment before we respond.
Option 01, with option 02 in parallel. Rationale: the evidence gap is the structural problem; the field re-brief holds the position while the review runs.
Shared as
Ariya understands the sources, evidence types, competitive events and strategic questions pharmaceutical teams work with.
Every important conclusion can be reviewed against its supporting sources.
The same intelligence can be translated into the version leadership, brand, medical or field teams need.
Ariya helps structure the response and retain the decision history, not merely report that something happened.
We moved from reporting to decision-ready narratives. Ariya changed how our insights team shows up in cross-functional forums.
Head of Insights & Analytics, Large Dermatology Company
Monitoring tools find information and deliver it. Ariya starts where they stop: it connects each signal to your markets and strategy, explains why it matters, proposes response options with their trade-offs, and keeps the decision and rationale alongside the evidence.
A general model answers the question you remember to ask. Ariya maintains a standing watch on a competitive field you define, keeps a record of what was previously concluded, states the basis for its confidence, and gives colleagues a shared view they can open and check.
Yes. Conclusions stay connected to the public sources behind them, and confidence is reported as coverage, freshness and inference depth rather than a single number — so you can see whether an assessment rests on thin recent evidence or deep older evidence.
The competitors, products and markets you want watched, your indication and strategic context, and who needs to receive what. Ariya works from public sources, so no confidential data is required to start. We scope the field with you in the first session.
Choose the competitors, markets or strategic questions that matter to you. We will show how Ariya moves from signal to interpretation, recommendation and decision support.